Skip to main content

View full-text article in PMC

. 2023 May 26;129(2):309–317. doi: 10.1038/s41416-023-02276-0

Table 3.

Thromboembolic events.

GSK3368715 dose^a	Primary neoplasm at diagnosis	Thromboembolic event	Grade	Anticoagulation status
GSK3368715 dose^a	Primary neoplasm at diagnosis	Thromboembolic event	Grade	Started prior to study treatment	Stated medication(s)
50 mg	Cholangiocarcinoma	Portal vein thrombosis	2	Not known	Not known
100 mg	Pancreas adenocarcinoma	Pulmonary embolism	3	No	Enoxaparin 40 mg QD intramuscularly
100 mg	Head and neck squamous cell carcinoma	Pulmonary embolism^b	2	No	Bemiparin 7500 units intradermally
200 mg	Pancreas adenocarcinoma mucinous	Pulmonary embolism^c	5	No	Heparin 25,000 units continuous infusion Enoxaparin sodium 60 mg BID subcutaneously Rivaroxaban 15 mg QD oral
	Colon/rectum adenocarcinoma	Portal vein thrombosis Pulmonary embolism	3 3	No	Enoxaparin sodium 60 mg BID subcutaneously
	NSCLC adenocarcinoma	Aortic thrombosis^d,e Portal vein thrombosis	3 3	No	Enoxaparin sodium 60 mg BID subcutaneously
	Mucoepidermoid carcinoma of parotid	Pulmonary embolism	3	No	Enoxaparin sodium 60 mg BID subcutaneously edoxaban 60 mg QD oral
	Epithelioid hemangioendothelioma	Pulmonary embolism	3	No	Enoxaparin sodium 60 mg BID subcutaneously Rivaroxaban 15 mg QD oral
	Prostate adenocarcinoma	Deep vein thrombosis^d,e Pulmonary embolism	3 3	No	Enoxaparin sodium QD subcutaneously Rivaroxaban 15 mg QD oral

BID twice daily, QD once daily.

^an = 24.

^bStudy drug withdrawn.

^cFatal.

^dPossibly study drug related.

^eDose interrupted.